68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
Recruiting · NCT07209878 · Interventional (participants receive a specific treatment) · Lead sponsor: First Affiliated Hospital of Fujian Medical University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).
Who can take part
Age range
18 Years to 80 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2, Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Biopsy-confirmed adenocarcinoma of the prostate.
- No anti-tumor treatment received prior to the PET imaging.
- Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.
- Radical prostatectomy scheduled within 28 days after PET imaging
Exclusion criteria
- Patients with other malignant tumors
- Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.
Where it is running
1 location listed.
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University - Fuzhou, Fujian, China